The Miami Myeloma MRD 2021 Virtual Meeting will take place on October 13, 2021
at 9am EDT/2pm BST/3pm CEST. Organized by the Multiple Myeloma Research Foundation & Sylvester Comprehensive Cancer Center, the meeting will bring together leading experts in multiple myeloma who will discuss the use of measurable residual disease (MRD) in clinical and trial settings, furthering our understanding of recent advances in the disease, and encouraging interactive discussion.

VJHemOnc is pleased to be the official media partner for the meeting.

This event is intended for Healthcare Professionals only and registration is subject to approval. Please apply for registration below and you will get a confirmation by email.

Meeting Chairs:
Ola Landgren (Co-Lead) USA, Daniel Auclair (Co-Lead) USA, Dickran Kazandjian, USA.

Find out what to look forward to at the meeting from Daniel Auclair:

Agenda (Eastern Time):

9:00AM – 9:10AM
1. Welcome and introduction (Ola Landgren)

9:10AM- 9:20AM
2. Biology of MRD (Francesco Maura)

3. New MRD technologies, focus on myeloma (Chair: Daniel Auclair)

9:20AM-9:30AM
A) NGS-based MRD: Applications in Myeloma  – Lanny Kirsch

9:30AM – 10:10AM
B) Proteomics

i. MSKCC approach/Binding Site – Katie Thoren
ii. UHN approach/EasyM – Suzanne Trudel
iii. Mayo Clinic Approach/Mass-Fix – Angela Dispenzieri
iv. Sylvester approach/Q-TOF – Lisa Reidy

10:10AM – 11:00AM
C) Liquid biopsies

i. DFCI approach – Irene Ghobrial
ii. UHN Approach – Trevor Pugh
iii. Stanford approach – David Kurtz
iv. Sylvester approach – David Coffey

11:00AM – 11:30AM
D) Imaging

i. MRI – Jens Hillengass
ii. Immuno-PET – Gary Ulaner
iii. Imaging the tumor and the micro-environment – Peter Choyke

11:30AM – 12:00PM
Panel discussion on topic

12:00PM – 12:05PM
Break

12:05PM – 12:25PM
Lunch (fireside chat with Nicole Gormley & Ola Landgren)

4. MRD in various trial settings, latest updates (Chair: Dickran Kazandjian)

12:25PM – 12:45PM
A) Smoldering myeloma

i. PETHEMA trial – Marivi Mateos
ii. NCI trial – Dickran Kazandjian

12:45PM – 2:00PM
B) NDMM setting

i. GRIFFIN — Peter Voorhees
ii. MASTER – Luciano Costa
iii. Manhattan trial – Neha Korde
iv. FORTE – Stefania Oliva
v. IFM2009 update – Aurore Perrot
vi. New CTN trial – Saad Usmani
vii. New ADVANCE trial – Elisabet Manasanch
viii. MRD – Pfizer experience – Ed Chan (PFE)

2:00PM – 2:20PM
C) Maintenance setting

i. SWOG 1803 — Amrita Krishnan
ii. MSKCC long-term lenalidomide maintenance – Benjamin Diamond

2:20PM – 2:50PM
Panel Discussion: Current and future role of MRD in clinical trials?

2:50PM – 2:55PM
Break

2:55PM – 3:25PM
5. MRD in daily practice: today and tomorrow

i. Univ Chicago – Benjamin Derman
ii. UCSF – Nina Shah
iii. Mayo Clinic, Scottsdale – Rafael Fonseca

3:25 PM –3:35PM
6. Brief summary, next steps, and adjourn (Ola Landgren)

This meeting has been supported by the following sponsors: